Outcomes following progression on BRAF/MEK inhibition in metastatic melanoma.

被引：2
|
作者：
Mason, Robert
Heng, Sharon
Atkinson, Victoria
机构：
[1] Princess Alexandra Hosp, Brisbane, Qld, Australia
[2] Univ Queensland, Brisbane, Qld, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.9537
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9537
引用
收藏
页数：5
相关论文
共 50 条
  • [1] Inhibition of BRAF and BRAF+MEK drives a metastatic switch in melanoma
    Smalley, Keiran S. M.
    Fedorenko, Inna V.
    [J]. MOLECULAR & CELLULAR ONCOLOGY, 2015, 2 (04)
  • [2] BRAF with or without MEK inhibition plus PD-1 checkpoint blockade for the treatment of metastatic melanoma.
    Rohlfs, Michelle
    Bassett, Roland L.
    Lacey, Carol
    McQuail, Natalie
    Mehta, Urvi
    John, Ida
    Simien, Rinata
    Tupue, Stephanie
    Dett, Tina Karin
    Glitza, Isabella Claudia
    Diab, Adi
    Amaria, Rodabe Navroze
    Tawbi, Hussein Abdul-Hassan
    Davies, Michael A.
    Hwu, Wen-Jen
    Hwu, Patrick
    Patel, Sapna Pradyuman
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [3] Toxicities with combination BRAF and MEK inhibition in resected stage III melanoma.
    Warrier, Govind
    Homan, Morgan
    Lao, Christopher D.
    Yentz, Sarah Elizabeth
    Kraft, Shawna
    Fecher, Leslie Anne
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [4] Combined BRAF and MEK inhibition for the treatment of BRAF-mutated metastatic melanoma
    Queirolo, Paola
    Picasso, Virginia
    Spagnolo, Francesco
    [J]. CANCER TREATMENT REVIEWS, 2015, 41 (06) : 519 - 526
  • [5] COMBINED BRAF AND MEK INHIBITION IMPROVES OUTCOME IN METASTATIC MELANOMA
    不详
    [J]. CANCER DISCOVERY, 2012, 2 (11) : 971 - 971
  • [6] Inhibition of Mutated BRAF in Melanoma.
    Kim, Taegyun
    Kim, Jihyun
    Lee, Min-Geol
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (23): : 2261 - 2261
  • [7] Metabolic tumor burden for prediction of overall survival following combined BRAF/MEK inhibition in patients with advanced BRAF mutant melanoma.
    McArthur, Grant A.
    Callahan, Jason
    Ribas, Antoni
    Gonzalez, Rene
    Pavlick, Anna C.
    Hamid, Omid
    Gajewski, Thomas
    Puzanov, Igor
    Daud, Adil
    Yin, Ming
    Choong, Nicholas
    Shah, Jinay K.
    Fredrickson, Jill
    Hicks, Rodney J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [8] BRAF and MEK inhibition in melanoma
    Dossett, Lesly A.
    Kudchadkar, Ragini R.
    Zager, Jonathan S.
    [J]. EXPERT OPINION ON DRUG SAFETY, 2015, 14 (04) : 559 - 570
  • [9] OUTCOMES FOLLOWING CESSATION OF BRAF ± MEK INHIBITION AFTER ACHIEVING COMPLETE RESPONSE IN BRAF MUTANT ADVANCED MELANOMA
    Girgis, C.
    Vanella, V.
    Menzies, A. M.
    Guminski, A.
    Kefford, R. F.
    Long, G. V.
    Ascierto, P.
    Carlino, M. S.
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 : 41 - 41
  • [10] Risk of disease progression (PD) following discontinuation of BRAF±MEK targeted therapies for reasons other than PD in patients (pts) with metastatic or unresectable melanoma.
    Corti, Francesca
    Randon, Giovanni
    Bini, Marta
    Raimondi, Alessandra
    Manglaviti, Sara
    Zattarin, Emma
    Bisogno, Ilaria
    Vetrano, Irene
    Cimminiello, Carolina
    De Braud, Filippo G.
    Del Vecchio, Michele
    Di Guardo, Lorenza
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345